Abbott Laboratories (NYSE: ABT) faced a 3.0% decline in stock price this morning despite reporting a strong second quarter and raising its full-year guidance. Meanwhile, CEO Robert B. Ford thinks the overall optimism around Abbott is because of the company’s promising product pipeline, particularly a new over-the-counter product called Lingo. Lingo: A potential game-changer Lingo… Continue reading Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product
Stock Research
Ken Griffin’s $44.6 million stegosaurus skeleton acquisition sets auction record
Billionaire investor Ken Griffin, renowned for his acquisitions, made headlines by purchasing a late-Jurassic stegosaurus skeleton named “Apex” at Sotheby’s auction for a record-breaking $44.6 million. This acquisition marks the highest price ever paid for a fossil at auction, surpassing initial estimates by a significant margin. Apex: A remarkable specimen “Apex,” a remarkable specimen dating… Continue reading Ken Griffin’s $44.6 million stegosaurus skeleton acquisition sets auction record
Netflix Q2 earnings preview: Wall Street awaits updates on ad-supported model
Netflix is set to report its second-quarter earnings after the bell on Thursday, and all eyes are on the streaming giant’s progress with its advertising-supported business model. Launched in late 2022, the ad-supported tier is seen as a critical component of Netflix’s strategy to boost revenue and profitability. Wall Street analysts are keen to hear… Continue reading Netflix Q2 earnings preview: Wall Street awaits updates on ad-supported model
Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy
Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cancer combination therapy. Despite the setback, the company remains committed to exploring alternative pathways to bring this promising treatment… Continue reading Agenus stock plummets over 50% as FDA rejects accelerated approval for BOT/BAL cancer therapy
Domino’s Pizza stock crashes as American consumer struggles with rising food prices
Domino’s Pizza (DPZ) stock price is down over 13% during trading today as investors absorb the shocking earnings report. The company reported an EPS beat and almost achieved the sales targets. However, a weak guidance and suspension of new store opening targets has investors worried. The EPS clocked in at $4.03 beating expectations by 9.6%… Continue reading Domino’s Pizza stock crashes as American consumer struggles with rising food prices
Amazon Prime Day 2024 smashes sales records with $14 billion; stock declines despite high demand
Amazon.com Inc (NASDAQ: AMZN) faced a slight decline in stock value today despite achieving record-breaking sales during Prime Day 2024, which saw customers spend over $14 billion across its platform. The eCommerce giant reported a surge in Prime members participating in this year’s event, marking a significant increase from previous years. Notably, shoppers showed a… Continue reading Amazon Prime Day 2024 smashes sales records with $14 billion; stock declines despite high demand
Short TXN: Texas Instruments Faces Rejection at $205, Short-Term Retest of $200 Expected
SEC moves court against Trump Media SPAC ex-CEO Patrick Orlando
The US Securities and Exchange Commission (SEC) has filed a lawsuit against Patrick Orlando, the former CEO of Digital World Acquisition Corp. (DWAC), a blank-check company that merged with Trump Media. The SEC accuses Orlando of making false statements regarding the company’s merger plans with Donald Trump’s social media startup, Truth Social. SEC lawsuit highlights… Continue reading SEC moves court against Trump Media SPAC ex-CEO Patrick Orlando